| Multiple Myeloma
Xgeva vs Carvykti
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Xgeva vs Carvykti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCarvykti has a higher rate of injection site reactions vs Xgeva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Carvykti but not Xgeva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xgeva
Carvykti
At A Glance
SC injection
Every 4 weeks
RANKL inhibitor
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
Indications
- Multiple Myeloma
- Metastatic malignant neoplasm to bone
- Giant Cell Tumor of Bone
- Humoral hypercalcemia of malignancy (disorder)
- Multiple Myeloma
Dosing
Multiple Myeloma, Metastatic malignant neoplasm to bone 120 mg SC every 4 weeks in the upper arm, upper thigh, or abdomen.
Giant Cell Tumor of Bone, Humoral hypercalcemia of malignancy (disorder) 120 mg SC every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy, in the upper arm, upper thigh, or abdomen.
Multiple Myeloma 0.5-1.0x10^6 CAR-positive viable T cells/kg IV (max 1x10^8 cells) as a single infusion, administered 2-4 days after lymphodepleting chemotherapy (cyclophosphamide 300 mg/m^2 IV and fludarabine 30 mg/m^2 IV daily for 3 days); premedicate with acetaminophen and an H1-antihistamine 30-60 minutes prior to infusion.
Contraindications
- Pre-existing hypocalcemia
- Known clinically significant hypersensitivity to Xgeva or denosumab products
—
Adverse Reactions
Most common (>=25%) Fatigue/asthenia, hypophosphatemia, nausea
Serious Dyspnea, osteonecrosis of the jaw, hypocalcemia, atypical subtrochanteric and diaphyseal femoral fracture, multiple vertebral fractures following treatment discontinuation
Postmarketing Severe symptomatic hypocalcemia (including fatal cases), severe symptomatic hypercalcemia following treatment discontinuation, hypersensitivity including anaphylactic reactions, severe musculoskeletal pain, lichenoid drug eruptions, alopecia
Most common (>20%) Pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, vomiting
Serious Pneumonia, cytokine release syndrome, sepsis, encephalopathy, viral infection, cranial nerve palsies
Postmarketing T cell malignancies including T-cell lymphoma, immune effector cell-associated enterocolitis and gastrointestinal perforation, infusion related reactions, JC virus progressive multifocal leukoencephalopathy
Pharmacology
Xgeva is a RANKL inhibitor; it binds to RANKL, a protein essential for osteoclast formation, function, and survival, thereby preventing osteoclast-mediated bone resorption and modulating calcium release from bone in solid tumor bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.
CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a transgene encoding a CAR featuring two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain, and a CD3-zeta signaling domain; upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xgeva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Carvykti
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xgeva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Carvykti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xgeva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Carvykti
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xgeva.
Cost estimate not availableLeukemia & Lymphoma Society (LLS): Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CarvyktiView full Carvykti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.